Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
DM-919 by D2M Biotherapeutics for Solid Tumor: Likelihood of Approval
DM-919 is under clinical development by D2M Biotherapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...